BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 20460910)

  • 1. Chemokines as immune mediators of liver diseases related to the metabolic syndrome.
    Berres ML; Nellen A; Wasmuth HE
    Dig Dis; 2010; 28(1):192-6. PubMed ID: 20460910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2.
    Haukeland JW; Damås JK; Konopski Z; Løberg EM; Haaland T; Goverud I; Torjesen PA; Birkeland K; Bjøro K; Aukrust P
    J Hepatol; 2006 Jun; 44(6):1167-74. PubMed ID: 16618517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic potential of chemokine receptor antagonists for liver disease.
    Sahin H; Berres ML; Wasmuth HE
    Expert Rev Clin Pharmacol; 2011 Jul; 4(4):503-13. PubMed ID: 22114859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection.
    Zeremski M; Petrovic LM; Talal AH
    J Viral Hepat; 2007 Oct; 14(10):675-87. PubMed ID: 17875002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serotonin mediates oxidative stress and mitochondrial toxicity in a murine model of nonalcoholic steatohepatitis.
    Nocito A; Dahm F; Jochum W; Jang JH; Georgiev P; Bader M; Renner EL; Clavien PA
    Gastroenterology; 2007 Aug; 133(2):608-18. PubMed ID: 17681180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pathogenesis of liver fibrosis: modulation of stellate cells by chemokines].
    Wasmuth HE; Weiskirchen R
    Z Gastroenterol; 2010 Jan; 48(1):38-45. PubMed ID: 20072995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease.
    Liew PL; Lee WJ; Lee YC; Wang HH; Wang W; Lin YC
    Obes Surg; 2006 Dec; 16(12):1584-93. PubMed ID: 17217634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.
    Cong WN; Tao RY; Tian JY; Liu GT; Ye F
    Life Sci; 2008 May; 82(19-20):983-90. PubMed ID: 18417155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemokine-directed immune cell infiltration in acute and chronic liver disease.
    Karlmark KR; Wasmuth HE; Trautwein C; Tacke F
    Expert Rev Gastroenterol Hepatol; 2008 Apr; 2(2):233-42. PubMed ID: 19072358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Kupffer cells reduced CXC chemokine production and liver injury.
    Mosher B; Dean R; Harkema J; Remick D; Palma J; Crockett E
    J Surg Res; 2001 Aug; 99(2):201-10. PubMed ID: 11469888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CCR5 and CXCR3 are dispensable for liver infiltration, but CCR5 protects against virus-induced T-cell-mediated hepatic steatosis.
    Holst PJ; Orskov C; Qvortrup K; Christensen JP; Thomsen AR
    J Virol; 2007 Sep; 81(18):10101-12. PubMed ID: 17626099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amelioration of non-alcoholic steatohepatitis and glucose intolerance in ob/ob mice by oral immune regulation towards liver-extracted proteins is associated with elevated intrahepatic NKT lymphocytes and serum IL-10 levels.
    Elinav E; Pappo O; Sklair-Levy M; Margalit M; Shibolet O; Gomori M; Alper R; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
    J Pathol; 2006 Jan; 208(1):74-81. PubMed ID: 16261527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin resistance and metabolic syndrome in chronic liver diseases: old entities with new implications.
    Tsochatzis EA; Manolakopoulos S; Papatheodoridis GV; Archimandritis AJ
    Scand J Gastroenterol; 2009; 44(1):6-14. PubMed ID: 18661429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Animal models of NASH: getting both pathology and metabolic context right.
    Larter CZ; Yeh MM
    J Gastroenterol Hepatol; 2008 Nov; 23(11):1635-48. PubMed ID: 18752564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roles for chemokines in liver disease.
    Marra F; Tacke F
    Gastroenterology; 2014 Sep; 147(3):577-594.e1. PubMed ID: 25066692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemokines in liver inflammation and fibrosis.
    Wasmuth HE; Tacke F; Trautwein C
    Semin Liver Dis; 2010 Aug; 30(3):215-25. PubMed ID: 20665374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonalcoholic fatty liver disease in severely obese subjects.
    Gholam PM; Flancbaum L; Machan JT; Charney DA; Kotler DP
    Am J Gastroenterol; 2007 Feb; 102(2):399-408. PubMed ID: 17311652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathology of nonalcoholic fatty liver disease.
    Yeh MM; Brunt EM
    Am J Clin Pathol; 2007 Nov; 128(5):837-47. PubMed ID: 17951208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemokine expression during the development and resolution of a pulmonary leukocyte response to influenza A virus infection in mice.
    Wareing MD; Lyon AB; Lu B; Gerard C; Sarawar SR
    J Leukoc Biol; 2004 Oct; 76(4):886-95. PubMed ID: 15240757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of cytokines in non-alcoholic steatohepatitis. A review.
    Copaci I; Micu L; Voiculescu M
    J Gastrointestin Liver Dis; 2006 Dec; 15(4):363-73. PubMed ID: 17205149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.